TP53 and non-small cell lung carcinoma: Another evidence to support that MDM2 targeted treatment is uniquely effective in wtTP53 NSCLC cells is shown in Figure 3D, as inhibition of the wild‐type TP53 by pifithrin‐α (a selective TP53 inhibitor) in A549 and NCI‐H460 cells counteracted the anti‐proliferative activity of RG7388.